Subscribe
shutterstock_1862407378_ralf_liebhold
Ralf Liebhold / Shutterstock.com
17 March 2022AmericasMuireann Bolger

Teva can pursue migraine patent dispute against Eli Lilly

Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly secures trade secret suit dismissal
27 September 2022   Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.
Big Pharma
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13 January 2022   Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Eli Lilly secures trade secret suit dismissal
27 September 2022   Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.
Big Pharma
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13 January 2022   Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.

More on this story

Americas
Eli Lilly secures trade secret suit dismissal
27 September 2022   Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.
Big Pharma
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13 January 2022   Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB